Kisqali, fulvestrant combo meets overall survival endpoint in MONALEESA-3
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients | Novartis
Overall survival (OS) results of the Phase III MONALEESA-3 trial - YouTube
Asco 2019 – Novartis looks to premenopausal survival to reinvigorate Kisqali | Evaluate
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer | NEJM
MONALEESA-3: Updated Survival
MONALEESA-3 OS Update - Capsule Summary Slidesets - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
YIR On Demand Breast Hope S Rugo MD
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
ESMO 2019: MONALEESA-3 Update Demonstrates Activity of Ribociclib for Breast Cancer in Postmenopausal Setting | PracticeUpdate
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Efficacy of KISQALI® (ribociclib) + Fulvestrant in Postmenopausal | HCP
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
ESMO复盘，这些重磅研究你都知道吗？_腾讯新闻
Download Poster: Overall Survival with Kisqali® plus Endocrine Therapy in Patients with Advanced Breast Cancer with Visceral Metastases 6
BOOG Study Center - Studie
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positi
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
